FDA officially pulls Zantac and all ranitidine medications

FDA officially pulls Zantac and all ranitidine medications

| Apr 14, 2020 | Products Liability |

The U.S. Food and Drug Administration (FDA) has made it official and pulled all ranitidine medications, the most well-known of which runs under the brand name of Zantac. It is a popular heartburn medication, or at least it was before tests discovered that it contained N-Nitrosodimethylamine (NDMA), which is a carcinogen. 

Though Zantac is an Over-The-Counter (OTC) medication, this ruling by the FDA applies to both OTC options and prescription medications. Those prescriptions can’t be filled any longer and retailers need to pull any remaining products from shelves. 

The issue is that some ranitidine products have an impurity level that exceeds safety standards. It appears that the impurity can get worse over time if the medication ever gets stored in a location that is above room temperature. 

This issue began last fall, and warnings went out in September of 2019. At that time, many stores decided to stop selling the medication anyway, so they may not need to take any further action. However, the FDA needed more time to conduct a full-scale investigation. Now that it has concluded, they’re making things official and saying that the medication is just too dangerous for consumers to use. 

It should be noted that you can find NDMA in water, food and other such sources. However, it is always at a low level that is deemed safe. The change to higher levels with storage is what really makes Zantac so dangerous. 

Have you or a loved one suffered an injury from the use of Zantac or gotten cancer after consistent use? Be sure you know what legal options you have